Maternal and Perinatal Outcomes of SARS-CoV-2 and Variants in Pregnancy

Pregnancy is a physiological state that predisposes women to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,a disease that can cause adverse maternal and perinatal outcomes.The severity of coronavirus disease 2019 (COVID-19) disease is known to vary by viral strain;however,evidence for the effects of this virus in pregnant women has yet to be fully elucidated.In this review,we describe maternal and perinatal outcomes,vaccination,and vertical transmission,among pregnant women infected with the different SARS-CoV-2 variants identified to date.We also summarize existing evidence for maternal and perinatal outcomes in pregnant women with specific information relating to SARS-CoV-2 variants.Our analysis showed that Omicron infection was associated with fewer severe maternal and perinatal adverse outcomes while the Delta variant was associated with worse pregnancy outcomes.Maternal deaths arising from COVID-19 were found to be rare (<1.0%),irrespective of whether the virus was a wild-type strain or a variant.Severe maternal morbidity was more frequent for the Delta variant (10.3%),followed by the Alpha (4.7%),wild-type (4.5%),and Omicron (2.9%) variants.The rates of stillbirth were 0.8%,4.1%,3.1%,and 2.3%,respectively,in pregnancies infected with the wild-type strain,Alpha,Delta,and Omicron variants,respectively.Preterm birth and admission to neonatal intensive care units were more common for cases with the Delta infection (19.0% and 18.62%,respectively),while risks were similar for those infected with the wild-type (14.7% and 11.2%,respectively),Alpha (14.9% and 13.1%),and Omicron variants (13.2% and 13.8%,respectively).As COVID-19 remains a global pandemic,and new SARS-CoV-2 variants continue to emerge,research relating to the specific impact of new variants on pregnant women needs to be expanded.

HMGB3 is a potential diagnostic marker for early cervical lesion screening

Despite the spread of effective vaccination strategies,cervical cancer remains the second leading cause of cancer death among women aged 20 to 39.1 clinical diagnosis of cervical lesions relies on the P16INK4a(P16)marker,but its sensitivity to low-grade cervical intraepithelial neoplasia(CIN)is limited.Exploring more sensitive and specific molecular markers is still a challenge in cervical lesion screening.In this study,we found that HMGB3 could effectively label pathological cells in different cervical lesions,especially for early CIN.Therefore,HMGB3 has the potential to be used as a novel marker for the early screening of cervical lesions.